Presence of leukemic fusion genes (and hyperdiploidy) in BM-MSCs from a cohort of infants/children with cytogenetically distinct acute leukemia
| Patient ID | Diagnosis | Cytogenetics (fusion gene) | Age (months) | Fusion gene in MSCa | Positive cases in each diagnostic group |
| 1 | Pre–B-ALL | t(12;21) TEL-AML1 | 30 | NO | |
| 2 | Pre–B-ALL | t(12;21) TEL-AML1 | 24 | NO | |
| 3 | Pre–B-ALL | t(12;21) TEL-AML1 | 36 | NO | |
| 4 | Pre–B-ALL | t(12;21) TEL-AML1 | 42 | NO | |
| 5 | Pre–B-ALL | t(12;21) TEL-AML1 | 70 | NO | |
| 6 | Pre–B-ALL | t(12;21) TEL-AML1 | 84 | NO | 0/12 (0%) |
| 7 | Pre–B-ALL | t(12;21) TEL-AML1 | 42 | NO | |
| 8 | Pre–B-ALL | t(12;21) TEL-AML1 | 96 | NO | |
| 9 | Pre–B-ALL | t(12;21) TEL-AML1 | 60 | NO | |
| 10 | Pre–B-ALL | t(12;21) TEL-AML1 | 48 | NO | |
| 11 | Pre–B-ALL | t(12;21) TEL-AML1 | 30 | NO | |
| 12 | Pre–B-ALL | t(12;21) TEL-AML1 | 54 | NO | |
| 13 | M2-AML | t(8;21) AML1-ETO | 144 | NO | 0/1 (0%) |
| 14 | Pre–B-ALL | t(9;22) BCR-ABL | 72 | NO | |
| 15 | Pre–B-ALL | t(9;22) BCR-ABL | 48 | NO | |
| 16 | Pre–B-ALL | t(9;22) BCR-ABL | 60 | NO | 0/5 (0%) |
| 17 | Pre–B-ALL | t(9;22) BCR-ABL | 72 | NO | |
| 18 | Pre–B-ALL | t(9;22) BCR-ABL | 72 | NO | |
| 19 | T-ALL | Hyperdiploid | 30 | NO | |
| 20 | Pre–B-ALL | Hyperdiploid | 48 | NO | |
| 21 | Pre–B-ALL | Hyperdiploid | 24 | NO | |
| 22 | Pre–B-ALL | Hyperdiploid | 36 | NO | |
| 23 | Pre–B-ALL | Hyperdiploid | 36 | NO | 0/10 (0%) |
| 24 | Pre–B-ALL | Hyperdiploid | 48 | NO | |
| 25 | Pre–B-ALL | Hyperdiploid | 142 | NO | |
| 26 | Pre–B-ALL | Hyperdiploid | 24 | NO | |
| 27 | Pre–B-ALL | Hyperdiploid | 60 | NO | |
| 28 | Pre–B-ALL | Hyperdiploid | 18 | NO | |
| 29 | Pro–B-ALL | t(4;11) MLL-AF4 | 6 | YES (4%) | |
| 30 | Pro–B-ALL | t(4;11) MLL-AF4 | 11 | YES (7%) | 4/4 (100%) |
| 31 | Pro–B-ALL | t(4;11) MLL-AF4 | 6 | YES (7%) | |
| 32 | Pro–B-ALL | t(4;11) MLL-AF4 | 4 | YES (8%) | |
| 33 | M5-AML | t(9;11) MLL-AF9 | 180 | NO | |
| 34 | M5-AML | t(9;11) MLL-AF9 | 12 | NO | |
| 35 | M2-AML | t(9;11) MLL-AF9 | 7 | NO | 0/6 (0%) |
| 36 | M5-AML | t(10;11) MLL-AF10 | 15 | NO | |
| 37 | Pre–B-ALL | t(11;19) MLL-ENL | 7 | NO | |
| 38 | AML | t(11;19) MLL-ENL | 9 | NO |
| Patient ID | Diagnosis | Cytogenetics (fusion gene) | Age (months) | Fusion gene in MSCa | Positive cases in each diagnostic group |
| 1 | Pre–B-ALL | t(12;21) TEL-AML1 | 30 | NO | |
| 2 | Pre–B-ALL | t(12;21) TEL-AML1 | 24 | NO | |
| 3 | Pre–B-ALL | t(12;21) TEL-AML1 | 36 | NO | |
| 4 | Pre–B-ALL | t(12;21) TEL-AML1 | 42 | NO | |
| 5 | Pre–B-ALL | t(12;21) TEL-AML1 | 70 | NO | |
| 6 | Pre–B-ALL | t(12;21) TEL-AML1 | 84 | NO | 0/12 (0%) |
| 7 | Pre–B-ALL | t(12;21) TEL-AML1 | 42 | NO | |
| 8 | Pre–B-ALL | t(12;21) TEL-AML1 | 96 | NO | |
| 9 | Pre–B-ALL | t(12;21) TEL-AML1 | 60 | NO | |
| 10 | Pre–B-ALL | t(12;21) TEL-AML1 | 48 | NO | |
| 11 | Pre–B-ALL | t(12;21) TEL-AML1 | 30 | NO | |
| 12 | Pre–B-ALL | t(12;21) TEL-AML1 | 54 | NO | |
| 13 | M2-AML | t(8;21) AML1-ETO | 144 | NO | 0/1 (0%) |
| 14 | Pre–B-ALL | t(9;22) BCR-ABL | 72 | NO | |
| 15 | Pre–B-ALL | t(9;22) BCR-ABL | 48 | NO | |
| 16 | Pre–B-ALL | t(9;22) BCR-ABL | 60 | NO | 0/5 (0%) |
| 17 | Pre–B-ALL | t(9;22) BCR-ABL | 72 | NO | |
| 18 | Pre–B-ALL | t(9;22) BCR-ABL | 72 | NO | |
| 19 | T-ALL | Hyperdiploid | 30 | NO | |
| 20 | Pre–B-ALL | Hyperdiploid | 48 | NO | |
| 21 | Pre–B-ALL | Hyperdiploid | 24 | NO | |
| 22 | Pre–B-ALL | Hyperdiploid | 36 | NO | |
| 23 | Pre–B-ALL | Hyperdiploid | 36 | NO | 0/10 (0%) |
| 24 | Pre–B-ALL | Hyperdiploid | 48 | NO | |
| 25 | Pre–B-ALL | Hyperdiploid | 142 | NO | |
| 26 | Pre–B-ALL | Hyperdiploid | 24 | NO | |
| 27 | Pre–B-ALL | Hyperdiploid | 60 | NO | |
| 28 | Pre–B-ALL | Hyperdiploid | 18 | NO | |
| 29 | Pro–B-ALL | t(4;11) MLL-AF4 | 6 | YES (4%) | |
| 30 | Pro–B-ALL | t(4;11) MLL-AF4 | 11 | YES (7%) | 4/4 (100%) |
| 31 | Pro–B-ALL | t(4;11) MLL-AF4 | 6 | YES (7%) | |
| 32 | Pro–B-ALL | t(4;11) MLL-AF4 | 4 | YES (8%) | |
| 33 | M5-AML | t(9;11) MLL-AF9 | 180 | NO | |
| 34 | M5-AML | t(9;11) MLL-AF9 | 12 | NO | |
| 35 | M2-AML | t(9;11) MLL-AF9 | 7 | NO | 0/6 (0%) |
| 36 | M5-AML | t(10;11) MLL-AF10 | 15 | NO | |
| 37 | Pre–B-ALL | t(11;19) MLL-ENL | 7 | NO | |
| 38 | AML | t(11;19) MLL-ENL | 9 | NO |
Number in parentheses represents percentage of MSCs.